A Study of FB2001 for Inhalation in Healthy Chinese Adults
Status:
Not yet recruiting
Trial end date:
2022-12-30
Target enrollment:
Participant gender:
Summary
FB2001 is a novel inhalable preparation being developed for COVID-19 treatment. A
Double-Blinded, Randomized, and Placebo-Controlled Phase 1 Study to Assess the Safety,
Tolerability and Pharmacokinetics Profile of Single and Multiple Ascending Doses of FB2001 in
Healthy Chinese Adults